Bluefield Project

A non-profit medical research foundation dedicated to finding a treatment or cure for frontotemporal dementia (FTD).

[Bluefield Project @BluefieldProj]

335! We thank #NSP participants & their loved ones, participating @allftd investigators & their teams, sponsors, and the many others who made this achievement possible.

[Neurofilament Surveillance Project @NSP_Study]

The Neurofilament Surveillance Project has met its goal of enrolling 335 participants in its remote blood biomarker study on familial frontotemporal degeneration (#FTLD)! This is an important milestone in our efforts to identify and validate biomarkers for FTLD. @BluefieldProj

[Bluefield Project @BluefieldProj]

Are you attending#ISFTD2026 and want to talk progranulin-related research or therapeutic development, the @BluefieldProj team welcomes the chance to connect.

[Bluefield Project @BluefieldProj]

The Bluefield Project is heading to AFTD's 2026 FTD Research Roundtable (September 23-25, 2026) in Arlington, VA to discuss Biomarker Strategies for FTD Clinical Trials.

We look forward to connecting with attendees advancing progranulin and FTD research.

[Bluefield Project @BluefieldProj]

New workshop hosted by NINDS, NIA and NIAID
Date & time: June 1 & 2, 2026 from 10am to 5pm
Registration link:  https://t.co/WNf0AIv68K

[Bluefield Project @BluefieldProj]

A recent @ScienceMagazine article highlights the creation of the @BluefieldProj and progress over 17 years toward therapies for FTD caused by GRN mutations.
🔗 https://t.co/RDpwo4SREt
#FTDResearch #GRN #Progranulin #RareDiseaseResearch #BluefieldProject

[Bluefield Project @BluefieldProj]

𝐑𝐚𝐫𝐞 𝐃𝐢𝐬𝐞𝐚𝐬𝐞 𝐃𝐚𝐲 𝐰𝐚𝐬 𝐭𝐡𝐢𝐬 𝐩𝐚𝐬𝐭 𝐰𝐞𝐞𝐤𝐞𝐧𝐝.
Our commitment to progranulin-related #FTD research is year-round.

Awareness is important.
Sustained progress is essential. 💙

#RareDiseaseDay #FTDResearch #CureFTD

[Bluefield Project @BluefieldProj]

Kudos to @Being_Patient_ for this timely coverage of #progranulin (#GRN) FTD and the promising experimental therapeutics being tested in the clinic.

[Being Patient @Being_Patient_]

🧬 Mutations in the GRN gene are the most common #genetic cause of frontotemporal dementia (#FTD).

💊 Experimental pills and #gene therapies are vying to be the first to prevent and slow the #disease.

Here's more from @SpichakSimon: https://t.co/93jp7KhYd3 🔗

[Bluefield Project @BluefieldProj]

@fenghua_hu Great to see you, and looking forward to your leadership for GC 2028!

[Bluefield Project @BluefieldProj]

@BluefieldProj is attending the Gordon Research Conference for #FTD & Related Rare Dementias (Feb 15–20, 2026). Looking forward to connecting with researchers advancing progranulin & FTD science. Attending? Let’s meet. 📩 [email protected]
👉 https://t.co/pKZAl579jR

[Bluefield Project @BluefieldProj]

@BluefieldProj to speak at the #FNIH Biomarkers Consortium Symposium (Feb 9–10, Bethesda, MD).
Looking forward to discussions on biomarkers, collaboration, and advancing neurodegenerative disease research—including #FTD.

#Biomarkers #FTDResearch #CureFTD #BluefieldProject

[Bluefield Project @BluefieldProj]

Earlier this week, @EliLillyandCo discontinued investigational gene therapy LY3884963 (PR006) for 𝘎𝘙𝘕-FTD, citing lack of efficacy. Data to be shared at a future meeting.

Thank you to Lilly, Prevail Therapeutics, and trial participants.

#FTDResearch #GRN #CureFTD #CureFTD

[Bluefield Project @BluefieldProj]

Another meaningful way to get involved this year: listening, learning, and staying informed. 🎧 #FTD-focused podcasts and education—like the
@RememberMePodcast,
@AFTD’s Educational Webinars, and
@4theirthoughts' valuable perspectives from families, clinicians, and researchers.

[Bluefield Project @BluefieldProj]

Getting involved doesn’t always start in a lab—it often starts with community. Orgs like @AFTDHope, #CureGRN, @CureMaptFtd , @CurePSP, @End_the_Legacy, #RememberMePodcast and #ForTheirThoughtsFoundation provide vital advocacy, education, and support for families affected by #FTD.

[Bluefield Project @BluefieldProj]

It’s a new year—and a new way to learn about clinical trials. Clinical trials help determine whether new therapies are safe and effective, and participation moves #FTD research forward.
🔬 Explore 𝘎𝘙𝘕 clinical trials:
https://t.co/T8HVN8aU5V
#FTDResearch #ClinicalTrials #GRN

[Bluefield Project @BluefieldProj]

A new year is a natural time to turn intention into action.
Getting involved in FTD research — joining the @EndFTDregistry, studies like #ALLFTD and #GENFI, and exploring clinical trials helps move potential treatments forward.
🔗 https://t.co/T8HVN8aU5V

[Bluefield Project @BluefieldProj]

Attending the #JPM2026 Healthcare Conference next week?
If you’re working in #FTDResearch or therapeutic development, the Bluefield Project team would welcome the chance to connect.
📩 [email protected]

#JPMHealthcare #Biotech #Neurodegeneration #CureFTD

[Bluefield Project @BluefieldProj]

A new year doesn’t reset the work - it carries it forward. Progress is built over time through collaboration and sustained commitment. Our focus remains unchanged: advancing FTD research, together.
Happy New Year! - The Bluefield Team

[Bluefield Project @BluefieldProj]

📚📷 2025 Research Spotlight: Q4 Bluefield-supported Q4 publications advanced #FTDResearch across biomarkers, brain structure, and functional networks—strengthening diagnosis and disease tracking. This post wraps up our 2025 Year-End Research series. 📷💙

[Bluefield Project @BluefieldProj]

❄️ This holiday season, we’re grateful for the researchers, clinicians & collaborators advancing FTD science. Progress happens through collaboration. Wishing you a peaceful holiday season.
#FTDResearch #CureFTD #BluefieldProject

[Bluefield Project @BluefieldProj]

📚🔬 2025 Research Spotlight: Q3
Bluefield-supported Q3 publications advanced #FTD research across molecular mechanisms, biomarkers, brain connectivity + global risk factors—from cellular biology to population-level insights. Proud to support this science. 💙
#FTDResearch

[Bluefield Project @BluefieldProj]

📚🔬 𝟐𝟎𝟐𝟓 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐒𝐩𝐨𝐭𝐥𝐢𝐠𝐡𝐭: 𝐐𝟐
Q2: The Bluefield Project-supported publications advanced FTD research across genetics, biomarkers, proteomics, digital health, and disease models—moving the field closer to treatments 💙
#FTDResearch #CureFTD